Smith Jeannina, Andes David
Department of Medicine, Section of Infectious Diseases, University of Michigan, Ann Arbor, Michigan, USA.
Ther Drug Monit. 2008 Apr;30(2):167-72. doi: 10.1097/FTD.0b013e318167d0e0.
Therapeutic drug monitoring of any pharmacologic agent should be considered when there is both significant pharmacokinetic variability and strong, clinically relevant, exposure-effect relationships. Many antifungal drugs exhibit marked variability in drug concentration as a result of inconsistent absorption, metabolism, elimination, or interaction with concomitant medications. For each of the available antifungal drugs, both preclinical and clinical trials have exhibited a relationship between serum concentrations and treatment efficacy. For a smaller subset of compounds, a similar relationship has been identified for the toxicity. The kinetic variability among patients falls outside the therapeutic window for a group of four antifungal compounds. This review summarizes the current literature on therapeutic drug monitoring for these antifungal agents.
当存在显著的药代动力学变异性以及强烈的、临床相关的暴露-效应关系时,应考虑对任何药物进行治疗药物监测。许多抗真菌药物由于吸收、代谢、消除不一致或与同时使用的药物相互作用,导致药物浓度存在显著差异。对于每种可用的抗真菌药物,临床前和临床试验均已表明血清浓度与治疗效果之间存在关联。对于一小部分化合物,也已确定其毒性与血清浓度存在类似关系。一组四种抗真菌化合物在患者中的动力学变异性超出了治疗窗。本综述总结了有关这些抗真菌药物治疗药物监测的当前文献。